Equities Analysts Offer Predictions for RVMD FY2026 Earnings

Key Points

• Brookline Capital Markets forecasts Revolution Medicines will post FY2026 EPS of -$8.71, compared with the current consensus estimate of -$7.88; it maintains a Buy rating and a $318 price target.
• For the latest quarter, the company reported a loss of $1.90 per share, narrower than the $2.35 consensus loss, and revenue of $197.56 million versus estimates of $25.58 million.
• Analyst sentiment is broadly positive: MarketBeat reports a Moderate Buy consensus rating and an average price target of $263.15, while the article notes that the stock’s roughly $41 billion market cap leaves high expectations for growth.

Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) - Equities researchers at Brookline Capital Markets issued their FY2026 EPS estimates for shares of Revolution Medicines in a research report issued on Wednesday, November 4th. Brookline Capital Markets analyst L. Cann anticipates that the company will post earnings per share of ($8.71) for the year. Brookline Capital Markets currently has a "Buy" rating and a $318.00 price objective on the stock. The consensus estimate for Revolution Medicines' current full-year earnings is ($7.88) per share. Brookline Capital Markets also issued estimates for Revolution Medicines' Q4 2026 earnings at ($2.27) EPS, FY2027 earnings at ($5.10) EPS and FY2028 earnings at $0.73 EPS.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported ($1.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.35) by $0.45. The business had revenue of $197.56 million for the quarter, compared to analysts' expectations of $25.58 million. During the same quarter in the prior year, the company posted ($1.61) earnings per share.

A number of other equities research analysts also recently issued reports on the company. Bank of America decreased their price objective on Revolution Medicines from $265.00 to $264.00 and set a "buy" rating on the stock in a research report on Friday, October 9th. Oppenheimer lifted their target price on Revolution Medicines from $230.00 to $260.00 and gave the stock an "outperform" rating in a report on Thursday, August 27th. Wolfe Research reissued an "outperform" rating and set a $220.00 target price on shares of Revolution Medicines in a research report on Monday, August 10th. Morgan Stanley assumed coverage on Revolution Medicines in a research report on Thursday, September 10th. They set an "overweight" rating and a $255.00 target price on the stock. Finally, Royal Bank Of Canada increased their price target on Revolution Medicines from $260.00 to $321.00 and gave the company an "outperform" rating in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Revolution Medicines presently has an average rating of "Moderate Buy" and a consensus target price of $263.15.

Revolution Medicines Stock Performance

RVMD opened at $192.28 on Monday. The firm has a market cap of $41.59 billion, a P/E ratio of -21.11 and a beta of 1.44. Revolution Medicines has a 12 month low of $58.91 and a 12 month high of $224.31. The company has a current ratio of 8.36, a quick ratio of 8.34 and a debt-to-equity ratio of 0.44. The stock has a 50-day moving average of $196.88 and a 200 day moving average of $157.56.

Hedge Funds Weigh In On Revolution Medicines

Hedge funds have recently bought and sold shares of the business. Aberdeen Group plc grew its holdings in Revolution Medicines by 303.1% in the third quarter. Aberdeen Group plc now owns 576,371 shares of the company's stock worth $118,306,000 after purchasing an additional 433,393 shares during the last quarter. Allworth Financial LP increased its position in shares of Revolution Medicines by 9.0% during the third quarter. Allworth Financial LP now owns 2,442 shares of the company's stock worth $457,000 after purchasing an additional 202 shares in the last quarter. R Squared Ltd acquired a new position in shares of Revolution Medicines during the third quarter worth $304,000. Fifth Third Bancorp lifted its holdings in shares of Revolution Medicines by 56.2% during the 3rd quarter. Fifth Third Bancorp now owns 4,100 shares of the company's stock valued at $842,000 after purchasing an additional 1,475 shares during the last quarter. Finally, Maryland State Retirement & Pension System lifted its holdings in shares of Revolution Medicines by 14.6% during the 3rd quarter. Maryland State Retirement & Pension System now owns 11,608 shares of the company's stock valued at $2,383,000 after purchasing an additional 1,478 shares during the last quarter. Institutional investors own 94.34% of the company's stock.

Insiders Place Their Bets

In other news, Director Elizabeth M. Anderson sold 10,143 shares of the company's stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $193.04, for a total transaction of $1,958,004.72. Following the transaction, the director owned 4,333 shares of the company's stock, valued at approximately $836,442.32. This represents a 70.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Margaret A. Horn sold 4,967 shares of the stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $199.24, for a total value of $989,625.08. Following the completion of the sale, the chief operating officer owned 149,680 shares in the company, valued at approximately $29,822,243.20. The trade was a 3.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 290,991 shares of company stock valued at $59,422,765 over the last quarter. Corporate insiders own 7.60% of the company's stock.

Trending Headlines about Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Strong early Rasonque sales: Revolution Medicines reported $197.6 million in third-quarter revenue, beating estimates, with Rasonque generating that amount in just five weeks after its U.S. launch. The company said more than 5,000 patients had been treated. The quarterly loss per share also came in narrower than analysts expected. Zacks article on Q3 results and Rasonque uptake
• Positive Sentiment: Analyst targets moved higher: HC Wainwright raised its target to $350 and maintained a Buy rating. RBC lifted its target to $321 with an Outperform rating; Guggenheim, Truist and TD Cowen also raised targets and retained positive ratings. These revisions signal optimism about the drug’s commercial potential and pipeline. HC Wainwright recommendations RBC target increase
• Neutral Sentiment: Long-term opportunity, but expectations are high: Rasonque’s clinical results and potential expansion into other solid tumors support the pipeline outlook. However, commentary noted that RVMD’s roughly $40 billion valuation already reflects substantial expectations, making sustained launch growth and upcoming clinical results important. Seeking Alpha analysis of Q3 results
• Negative Sentiment: Some long-range forecasts were cut: Brookline Capital Markets lowered its FY2029 EPS estimate to $8.49 from $8.94 and its FY2030 estimate to $17.41 from $18.15, though it kept a Buy rating and a $318 target.

About Revolution Medicines

Revolution Medicines, Inc is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company's research centers on RAS proteins, which can contribute to the growth of many cancers.

The company's pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.